# MARKET_RESEARCH_LOG_2026-08-26

> Production GenGe V3.1.1 hourly scan handoff. Repository `main` remains the source of truth. This log records completed production artifacts and is not an automatic trading instruction.

## GenGe V3.1.1 production promotion and current-date dry-run

- Production decision: `PROMOTE_CONFIDENCE_GATE_ONLY`.
- Current version: `GEN_GE_V3_1_1_PRODUCTION`.
- Round 8 discovery passed all frozen thresholds. Round 9 confirmed PIT, confidence, Sharpe, drawdown, CAGR and cash requirements; full V3.2 was rejected because its 12-month SELL opportunity cost exceeded the frozen limit.
- The original immediate V3.1 SELL ladder remains active. LOW/INVALID valuation confidence now forces HOLD_REVIEW; Hard Gate FAIL still forces EXIT.

## 2026-08-26 20:09 CST — authoritative opportunity + CURRENT_HOLDINGS risk refresh

- Holdings universe: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞` only.
- `603658 安图生物`: WAIT / Formal BUY NO; accepted exact close remained 34.17 on 2026-08-25 because 2026-08-26 exact-close sources were inconsistent. H1 profit/cash-flow weakness and capacity-project reallocation remained blockers.
- `603369`: HOLD_REVIEW / NO ADD; accepted 2026-08-26 close 28.10.
- `001316`: HOLD; H1 fundamentals strong; exact 2026-08-26 close unverified.
- `600276`: HOLD_REVIEW; accepted 2026-08-26 close 46.74.
- `600406`: HOLD; accepted 2026-08-26 close 23.42.
- New REDUCE/EXIT: NONE.

## 2026-08-26 21:07 CST — post-close filing refresh

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. Tier remains WAIT; Formal BUY remains NO. No reliable second execution-grade exact 2026-08-26 close was established; fresh-data invariant remains binding. Existing H1 earnings/cash-flow and capital-allocation blockers remain controlling.
- No new execution-eligible A1/A2 candidate; no Formal BUY/ADD.

### Holdings risk delta

- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369`, `001316`, `600276`, `600406`.
- `600406 国电南瑞`: **HOLD -> HOLD_REVIEW (material downgrade; NOT REDUCE)** after the newly released 2026H1 report. Revenue 277.67亿 (+14.54% YoY), attributable profit 30.73亿 (+4.08%), deduct-profit 29.25亿 (+4.31%), but operating cash flow fell to 5.91亿 (-78.95%); gross margin 25.34% (-1.11ppt) and net margin 11.70% (-1.19ppt). Accepted 2026-08-26 close 23.42 CNY. Grid digitization/UHV demand and grid-control/customer-certification moat remain intact, so this is a cash-conversion/margin review trigger rather than hard-thesis invalidation. Return to HOLD if working-capital/collection timing explains the cash-flow drop and H2 cash conversion/margins normalize; escalate toward REDUCE only if cash conversion/margins continue deteriorating alongside weaker orders or competitive position.
- `603369 今世缘`: HOLD_REVIEW / NO ADD; no new filing or REDUCE/EXIT trigger.
- `001316 润贝航科`: HOLD; no new material thesis-break evidence; price-dependent action remains fail-closed because exact 2026-08-26 close is not independently accepted.
- `600276 恒瑞医药`: HOLD_REVIEW; latest pipeline evidence remains supportive; no new moat/pipeline break or REDUCE/EXIT trigger.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Notification decision

- Triggered because an existing holding (`600406`) had a material rating change from HOLD to HOLD_REVIEW after a fresh H1 filing. This is a review downgrade, not a sell instruction.

## 2026-08-26 22:07 CST — late filing / insider-sell risk refresh

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. WAIT; Formal BUY NO. No newly accepted execution-grade 2026-08-26 exact close; existing H1 earnings/cash-flow, capacity-project reallocation and valuation-confidence blockers remain controlling.
- No new A1/A2 in executable buy zone; no Formal BUY/ADD.

### Holdings risk delta

- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369`, `001316`, `600276`, `600406`.
- `001316 润贝航科`: **HOLD -> HOLD_REVIEW (governance/supply-overhang watch; NOT REDUCE)**. A newly surfaced 2026-08-27 pre-disclosure says director/GM 徐烁华 may sell up to 808,542 shares (0.50%), director/deputy GM 高木锐 up to 141,155 (0.09%), and 18 other natural-person shareholders up to 776,883 (0.48%), aggregate maximum about 1.07% of shares, during 2026-09-17 through 2026-12-16, stated reason own funding needs. This follows the controlling shareholder/actual controller reduction completed in May 2026, so repeated insider selling is a governance/expectation-gap negative and potential supply overhang. It does NOT by itself falsify the operating thesis: 2026H1 revenue/profit/deduct-profit/OCF remained strongly positive YoY and the announced selling is not a control-change event. Escalate to REDUCE only if selling is accompanied by deterioration in orders, margins/cash conversion, management continuity, or other evidence that insiders' behavior reflects weakening fundamentals; downgrade can be reversed if execution remains strong and the sell plan proves immaterial to operating quality. Exact 2026-08-26 close remains unverified, so no price-dependent sell/add action is emitted.
- `600406 国电南瑞`: remains **HOLD_REVIEW**, with H1 cash-conversion/margin review controlling; accepted close 23.42.
- `603369 今世缘`: remains **HOLD_REVIEW / NO ADD**; no new sell trigger.
- `600276 恒瑞医药`: remains **HOLD_REVIEW**; no new sell trigger.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Notification decision

- Triggered because a confirmed holding (`001316`) received a new material insider/shareholder reduction plan and therefore moved from HOLD to HOLD_REVIEW. This is not a REDUCE/EXIT instruction.

## 2026-08-26 23:08 CST — hourly opportunity + holdings risk refresh

### Data cutoff / reproducibility

- Repository `main` rules and truth sources re-read before execution: `AGENTS.md`, current V3.1/V3.1.1 framework artifacts, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, `V31_CANDIDATE_LEDGER.md`, `CURRENT_HOLDINGS.md`, and this current-date market log.
- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369`, `001316`, `600276`, `600406`.
- Public post-close quote/filing refresh cutoff: 2026-08-26 23:08 CST. Fresh-data invariant remains mandatory.

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. WAIT; Formal BUY NO. The 22:56 deep-review conclusion remains controlling: capacity-expansion termination is prudent defensive capital allocation but simultaneously direct evidence of slower demand growth, oversupply risk, homogeneous competition and procurement-price pressure. No new evidence reverses the weakened-demand/moat burden, and no independently accepted second exact 2026-08-26 15:00 close was recovered. Accepted execution-grade close remains 34.17 CNY on 2026-08-25; observed entry band remains 33.58–34.15; Bear/Base/Bull valuation remains pending normalized earnings and moat audit.
- Ledger delta: `RESEEN / NO MATERIAL CHANGE`; `last_seen=2026-08-26 23:08 CST`, `seen_count=14`, latest run_id `hourly-20260826-2308`.
- No new execution-eligible A1/A2; no UPGRADED/DOWNGRADED/INVALIDATED candidate; no Formal BUY/ADD.

### Holdings risk delta

- `603369 今世缘`: **HOLD_REVIEW / NO ADD**, accepted 2026-08-26 close 28.10 CNY. No new filing or evidence since the prior refresh triggers REDUCE/EXIT or restores the long-term demand burden.
- `001316 润贝航科`: **HOLD_REVIEW**, not REDUCE. Insider/shareholder sell-plan review remains controlling; operating thesis is not falsified. Exact 2026-08-26 close remains independently unverified, so price-dependent action stays fail-closed.
- `600276 恒瑞医药`: **HOLD_REVIEW**, accepted 2026-08-26 close 46.74 CNY. No new pipeline/moat break, governance event, or REDUCE/EXIT trigger surfaced after the prior refresh.
- `600406 国电南瑞`: **HOLD_REVIEW**, accepted 2026-08-26 close 23.42 CNY. H1 cash-conversion/margin review remains controlling; no new order/moat evidence escalates it to REDUCE/EXIT.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Production / CI health

- Latest observed `main` head before this persistence pass was `aac6c8715f1f332aa8c7f6392f84b33809945a83` (`Cover V3.1.1 production parity in existing GenGe CI`). Combined commit status returned no failure statuses; GitHub Actions query for that exact head SHA returned zero workflow runs. Recorded as `CI_NOT_RUN_FOR_HEAD / NOT_A_FAILURE`, not as a production-chain failure. A prior Auto Tag workflow for an earlier parity-test commit remained queued in the recent-runs feed, which is not sufficient evidence of scan distortion.

### Notification decision

- No notification trigger this round: no new A1/A2 in executable buy range; no new deep-research queue name; no material candidate valuation/entry-band change; no holding REDUCE/EXIT or hard-thesis invalidation; no confirmed production/data/CI failure that makes the scan unreliable.